Evidence map›Paper›PMID 31943436›Full record

ReviewGenes, chromosomes & cancer2020

Characterization of renal cell carcinoma-associated constitutional chromosome abnormalities by genome sequencing.

Philip S Smith, James Whitworth, Hannah West, Jacqueline Cook, Carol Gardiner, Derek H K Lim, Patrick J Morrison, R Gordon Hislop, Emily Murray, NIHR Rare Disease BioResource and 4 more

Open access · hybridAbstract readCase ReportsReview
In one paragraph

Review in Genes, chromosomes & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Philip S SmithDepartment of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.
James WhitworthDepartment of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.
Hannah WestDepartment of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.
Jacqueline CookDepartment of Clinical Genetics, Sheffield Children's Hospital, Sheffield, UK.
Carol GardinerWest of Scotland Genetics Services, Queen Elizabeth University Hospital, Glasgow, UK.
Derek H K LimWest Midlands Regional Genetics Service, Birmingham Women's and Children's National Health Service (NHS) Foundation Trust, Birmingham, UK.
Patrick J MorrisonNorthern Ireland Regional Genetics Service, Belfast City Hospital, Belfast Health & Social Care Trust, Belfast, UK.
R Gordon HislopEast of Scotland Regional Genetics Service, Ninewells Hospital, Dundee, UK.
Emily MurrayEast of Scotland Regional Genetics Service, Ninewells Hospital, Dundee, UK.
NIHR Rare Disease BioResourceNIHR BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
Marc TischkowitzDepartment of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.
Anne Y WarrenDepartment of Histopathology, Cambridge University NHS Foundation Trust and Cancer Research UK Cambridge Centre, Cambridge, UK.
Emma R WoodwardManchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Health Innovation Manchester, Manchester, UK.
Eamonn R MaherDepartment of Medical Genetics, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cancer Research UK Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.ORCID 0000-0002-6226-6918
University of Cambridge · GBNinewells Hospital · GBBelfast Health and Social Care Trust · GBCambridge University Hospitals NHS Foundation Trust · GBCancer Research UK Cambridge Center · GBNational Health Service · GBQueen Elizabeth University Hospital · GBSheffield Children's Hospital · GB

Funding

Cancer Research UKDepartment of Health IS‐BRC‐1215‐20 007
6 · The paper itself

Abstract

Constitutional translocations, typically involving chromosome 3, have been recognized as a rare cause of inherited predisposition to renal cell carcinoma (RCC) for four decades. However, knowledge of the molecular basis of this association is limited. We have characterized the breakpoints by genome sequencing (GS) of constitutional chromosome abnormalities in five individuals who presented with RCC. In one individual with constitutional t(10;17)(q11.21;p11.2), the translocation breakpoint disrupted two genes: the known renal tumor suppressor gene (TSG) FLCN (and clinical features of Birt-Hogg-Dubé syndrome were detected) and RASGEF1A. In four cases, the rearrangement breakpoints did not disrupt known inherited RCC genes. In the second case without chromosome 3 involvement, the translocation breakpoint in an individual with a constitutional t(2;17)(q21.1;q11.2) mapped 12 Kb upstream of NLK. Interestingly, NLK has been reported to interact indirectly with FBXW7 and a previously reported RCC-associated translocation breakpoint disrupted FBXW7. In two cases of constitutional chromosome 3 translocations, no candidate TSGs were identified in the vicinity of the breakpoints. However, in an individual with a constitutional chromosome 3 inversion, the 3p breakpoint disrupted the FHIT TSG (which has been reported previously to be disrupted in two apparently unrelated families with an RCC-associated t(3;8)(p14.2;q24.1). These findings (a) expand the range of constitutional chromosome rearrangements that may be associated with predisposition to RCC, (b) confirm that chromosome rearrangements not involving chromosome 3 can predispose to RCC, (c) suggest that a variety of molecular mechanisms are involved the pathogenesis of translocation-associated RCC, and (d) demonstrate the utility of GS for investigating such cases.

Indexed as

Chromosome AberrationsAcid Anhydride HydrolasesAdultAgedBis(5'-adenosyl)triphosphataseCarcinoma, Renal CellChromosome BreakpointsChromosomes, Human, Pair 3FemaleGenetic TestingHumansKidney NeoplasmsMaleMiddle AgedNeoplasm ProteinsProtein Serine-Threonine KinasesAcid Anhydride HydrolasesBis(5'-adenosyl)triphosphataseFLCN protein, humanNeoplasm ProteinsNLK protein, humanProtein Serine-Threonine KinasesProto-Oncogene ProteinsRASGEF1A protein, humanras Guanine Nucleotide Exchange FactorsTumor Suppressor Proteinsgeneticsrenal cell carcinomatranslocationwhole genome sequencing

Identifiers

PMID31943436
PMCPMC7187337
OpenAlexW2999104475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.